## Bone Density Projecting Method Assisted 3D Simulation and Printing for Complex Pelvic and Acetabular Fractures: A Comparative Cohort Study

Lee Kai Xing Alvin, MD; Tsai Chun Hao, MD, PhD; Chen Hsien Te, Professor, MD, PhD

**Purpose**: Pelvic and acetabular fractures are considered complex surgeries due to their anatomical structure and mechanism of injuries. This study specifically applied (1) virtual reduction simulation, (2) bone density evaluation, and (3) 3D-printed models and evaluated their impact on intraoperative parameters and postoperative functional recovery and reduction quality of patients with complex comminuted pelvic and acetabular fractures using case-control studies.

**Methods**: 96 patients (aged 18 years and above) with comminuted pelvic or acetabular fracture (2018 AO/OTA 61C or 62B and above) were prospectively recruited and treated with either 3D printing or traditional approaches between 2017 and 2020 with a follow-up duration of 48 months. Clinical outcomes were evaluated using intraoperative blood loss, surgical duration, EQ-VAS (EuroQol visual analog scale), Majeed pelvic score, and EQ-5D-5L (EuroQol 5 dimensions 5 levels) scores. We further stratified postoperative outcomes by gender, age, ISS, blood loss, and surgical duration. The minimum follow-up duration was 48 months.

**Results**: 3D simulation and printing did not statistically improve intraoperative blood loss and surgical duration. However, complication rates were significantly lower in the 3D printing group (6.25% vs 23.4%, P = 0.047) with 15 patients in the traditional groups requiring revision surgeries. Furthermore, the 3D printing group had higher postoperative outcomes, including EQ-VAS (74.5 ± 19.4 vs 73.4 ± 21.1), Majeed Pelvic Score (77.5 ± 17.4 vs 72.3 ± 23.3), and EQ-5D-5L utility (0.72 ± 0.20 vs 0.58± 0.46). There were no differences in the stratification results except for the 6-h group whereby 3D printing had higher EQ-5D-5L scores. The cumulative incidence rate for 48 months was calculated using Kaplan-Meier analysis and 3D printing was reported to reduce complications by approximately 16%.

**Conclusion**: 3D simulation and printing did not improve intraoperative surgical parameters of patients with complex pelvic and acetabular fractures. However, there were satisfactory improvements in complication rates and postoperative outcomes after 48 months of follow-up.

The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical device they wish to use in clinical practice.

## POSTER ABSTRACTS



							nd 64 cases		p-value				0.226	0																					
							h 3D printing a		IR (95% CI)		00	reference)	.40 (0.09-																						5
							of patients with		ate, per H	00 person-	3.55 1.	÷	69																						SI I
							reen 32 cases o		son- R:	Su o	0.73 13		13 20			20 printing																			
							plication betw	approaches	ation Per	yca	110		35.			correctes .		200								٦									2
							idence of com	rith traditional	Complic	00	15		N			Traditional		og-tank p-value= 0										1		1	L		L	1	50
							Table 5. Inci	of patients v			Traditional		3D Printing			630		-	ij			63	aup	çaq	20	International de la construcción de	0	0.19			9		-	100	3
										ċ.	value		0000	0.960	100.0	107.0	0.067	667.0			0.918		. 404	0.587	0 202	0.000	I		0 100	66C'N	0.065	20010		0.043	
						comparing	nal			(95%	8		1 10 1	-10-01-	(/.01	(-0.40)	(1.0.00	1-0.09	1.000		(-21.4,		17.4)	(-24.4,	10.40	(-0.43)	1000		1.6.06	14.60	00 170	24.5)		(0.00,	165 0
						duration c	ith traditio		Adjusted	Estimate			010	61.0		711		71.0			-1.00			-7.41	110	11-0-	Ι		4 20	67+	911			0.29	
						ad surgical	patients w			ė.	value		0.007	C00'0	101.0	0.185	1000	107.0			0.549		0.000	106.0	0.2.0	0.060			0 460	200"0	0 190	0.000		0.136	
						lood loss at	54 cases of			÷ (95%	8		1111	14-14-7	10.8)	10 00	(9.85	(0.0)	1.00		(-15.7.		28.6)	(-19.7,	(0.11	·/c·n-)	100.0		(-12.2	1010	6674	31.1)	1	(-0.11.	0 72)
		_		1		I by ISS, bi	nting and (		Crude	Estimat			:	1.33		611		61.0			6.43			-1.12	000	60.0			4 80	1.00	12.2			0.30	
						e stratified	ith 3D pri	sion	ditional	an SD	-	32	1	5/11 7	200	7 20.0	10.0	07-0	51		6 21.6		404	5 18.5	0 0 0	10.0	17		0 00 9	0.77	6 264		_	5 0.61	
	, 0.583	0.385				e outcome	patients w	car regress	ng Tra	SD Me		z	10 67	10./ 01.	00 01	14.2 /8.		1.0 61.0	-N		72.5 67.0		44	.6/ 5.81	00 000	CT0 (770	2		17 80.	5	5 8 5	0.0	_	1.19 0.3.	
7.35)	(-7.36)	(-0.10	0.26)			ostoperativ	2 cases of	s using lin	<b>3D Printi</b>	Mean		N-13		070		7.05		co.0	N=8		74.0		4.10	/4.7	0.07	/0.0	Natl		40.4	t-20	70.8	200	-	0.66	
	2.82	0.08				Table 4. Pc	between 34	approaches				urgery time	* DOIL	EU-VAS		Majeed	0.00	EQ-5D-	merv time	S hour	EO-VAS			Majeed	EO CD	-ne-ha	more time	The hour	FO-VAS	CVA-DO	Maieod	Pelvic	Score	EQ-SD-	SL mility
	0.362	0.199						[	luc		88	2	24	Τ	316		T	587	3	4	17	1/1L 5	T	253		396	9	10			55	Τ	165	L	12
11.5)	(-6.00, 16.2)	(-0.07	0.34)		f notionte	n paucius		% D-	va		1.1, 0.0	6	3,	-	14, 0.	6	+	.0.			22	1 6		0		93. 0.1	(6	16, 0.	(8		5, 0.	0	.8, 0.0	-	26, 0.
	5.11	0.13			T crear o	r regressio	sted	nate (95	G	-	(-12	10.	3	19.	9	9.4	+	33	71		197	23	5	215	5.00	(-9.	n.	(-) (-)	0.12	-	-10	33.	2	37.	9
	23.3	0.46			or heat warman	ising linea	Adju	Estir	uc	-	47 -3.02		71 437	+	14 0.14	+	+	19 -2.68	00	00'0- C6	00 00	2	╞	46 44	2	55 0.70		45 0.01	_		65 7.80	+	80 6.24		35 0.38
	72.3	0.58				proaches u		-d %	val		8.4, 0.7	2)	2.0, 0.5	5	5.7, 0.3	8)		1.3, 0.7	(7	· · · ·	30 00	-	F	27 06	(2)	64, 0.6	(9	.14, 0.6	2)		3.8, 0.9	3)	6.1, 0.9	()	56, 0.5
	17.4	0.20			r and ana	itional app	de	mate (95	G	-	9 (-1	13.	-	21.	3	4.0	+	3	10		10	200	2	10 6	1.9	8-)	13.	0-)	0.2	-		35.	<u>.</u>	37.	2
	d 77.5	0.72			the name	s with trad	d Cru	D Esti			1.2 -2.5		3.6 4.75	+	0.16	+		1.1 2.45	100	16°C 0.C	20.0 44		╞	87 .23		1.8 2.50		36 0.04	_		3.1 075	+	4.4 0.45	-	57 0.24
VAS	Majee	EQ-51	SL		a cleatifia	of patient	Traditions	Mean S		N-42	72.0 2		71.1 2		0.54 0		N=22	76.2 2	010	1	0 44 0	200	N44	77.0 1		76.4 2		0 69 0		N-20	64.3 2		64.1		0.36 0
					uncontro en	1 64 cases .	inting	SD			24.9		21.4		0.21			13.2	3	ţ	010	2		183		15.4		0.19			35.4		37.5		0.30
					vitramit.	vinting and	3D Pr	Mean		N-18	.S 69.4		1 75.8		- 0.70		N=14	VS 78.6	0.02	0.0/	0.72	1	N=28	S 75.6		1 78.9		- 0.73		†2	S 65.0		1 64.5		- 0.61
					Tabla 2 De	with 3D pi				Mcn	EQ-VA		Majcoc		EQ-5D	SL	Women	EQ-VA	No.	majcor	EO.4D	15	Acecto	FO.VA	ſ	Majeed		EQ-5D	SL	Age>60	EQ-VA		Majcot		EQ-5D
						ng-model				value	083	371			356						047*	302			457	835				599	648				190
						vith 3D printi.		paches		4	7.4) 0.	0	1,4)	(9)	0.	5	(0)	5.5)	(1.	35)	3.4) 0.	0	(6.5	(13	09) 0.	0.	1.4)	1.4)	(2)	13.5) 0.	0	(0.0	3.4)	(9)	98) 0.
						's of patients v		ditional Appr.	54	-	0 (1)		(34	(0)			(4t	3	(1)	(9)	5		(3:	6)	9 (9.		ಲೆ	(3.	GL	3.5 (6)		(51	(2:	(2)	0 0.
						wccn 32 case.	pproaches.	Tra	N		(C		() 22	2) 42			1) 29	5) 23	2 (5	5) 4	5) 15		9) 23	1) 41	.11 (0		5) 22	3) 22	1) 20	.5) 806		5) 32	3) 15	1) 17	7) 4.40
						omparing bet-	h traditional a	rinting		-	(16.t		(43.8	(26.2			(31)	(40.4	(12.	(15.4	(6.2)		(46.5	(53.4	(11.4		(40.4	(31.	(28.1	7 (629		(40.4	(25.1	(34.	(23)
						of patients cu	f patients with	3D P	N=32		40.5		14	18	a		10	13	4	s	2		15	11	19.4		13	10	6	729.7		13	*	11	\$ 00
						Table 1. Demographics.	assisted and 64 cases of				Mcan age, year (SD)	Gender, n (%)	Women	Men	AO 2018 classification,	(%)	61C	62B	62C	Multiple	Complication, n (%)	ISS score,	<16	16+	Mcan (SD)	Blood loss, cc	<500	500-999	+0001	Mcan (SD)	Surgery time, hour	<4	4-5	- <del>1</del> 9	Mcan (SD)

See the meeting website for complete listing of authors' disclosure information. Schedule and presenters subject to change.